0000950170-24-030484.txt : 20240313
0000950170-24-030484.hdr.sgml : 20240313
20240313060407
ACCESSION NUMBER: 0000950170-24-030484
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240308
FILED AS OF DATE: 20240313
DATE AS OF CHANGE: 20240313
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: McNeill Jonathan
CENTRAL INDEX KEY: 0001824673
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39509
FILM NUMBER: 24744501
MAIL ADDRESS:
STREET 1: C/O DYNE THERAPEUTICS, INC.
STREET 2: 830 WINTER STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Dyne Therapeutics, Inc.
CENTRAL INDEX KEY: 0001818794
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 364883909
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1560 TRAPELO ROAD
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: (781) 786-8230
MAIL ADDRESS:
STREET 1: 1560 TRAPELO ROAD
CITY: WALTHAM
STATE: MA
ZIP: 02451
4
1
ownership.xml
4
X0508
4
2024-03-08
0001818794
Dyne Therapeutics, Inc.
DYN
0001824673
McNeill Jonathan
1560 TRAPELO ROAD
WALTHAM
MA
02451
false
true
false
false
Chief Business Officer
true
Common Stock
2024-03-08
4
M
false
86159
5.54
A
227343
D
Common Stock
2024-03-08
4
M
false
3841
5.54
A
231184
D
Common Stock
2024-03-08
4
S
false
34663
25.46
D
196521
D
Common Stock
2024-03-08
4
S
false
54648
26.72
D
141873
D
Common Stock
2024-03-08
4
S
false
689
27.31
D
141184
D
Common Stock
2024-03-11
4
M
false
17825
5.54
A
159009
D
Common Stock
2024-03-11
4
S
false
17825
25.48
D
141184
D
Common Stock
2024-03-11
4
S
false
1776
25.71
D
139408
D
Stock option (right to buy)
5.54
2024-03-08
4
M
false
86159
0
D
2030-07-30
Common Stock
86159
12309
D
Stock option (right to buy)
5.54
2024-03-08
4
M
false
3841
0
D
2030-07-30
Common Stock
3841
17825
D
Stock option (right to buy)
5.54
2024-03-11
4
M
false
17825
0
D
2030-07-30
Common Stock
17825
0
D
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.25 to $26.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.25 to $27.19, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $27.27 to $27.39, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.14 to $26.09, inclusive.
Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.67 to $25.81, inclusive.
Includes 132,976 unvested RSUs.
The option was granted on July 31, 2020. The shares underlying the option vest over four years in equal quarterly installments beginning on October 31, 2020.
The option was granted on July 31, 2020, with 100% of the option to vest upon the clearance date of an IND application submitted to the FDA by the Company with respect to one ofitsproduct candidates. On July 5, 2022, in connection with the clearance by the FDA of the Company's IND application for DYNE-251, the Compensation Committee determined thattheperformance condition had been achieved.
/s/ Richard Scalzo, Attorney-in-Fact
2024-03-12